[
  {
    "ts": null,
    "headline": "Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell",
    "summary": "Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read why PFE stock is a Sell.",
    "url": "https://finnhub.io/api/news?id=e4e4a458d4d5024fa4c4b1139ad3ff96dcd5046c6070aec049553cc8841d39a8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739755654,
      "headline": "Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell",
      "id": 132743406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403196687/image_1403196687.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read why PFE stock is a Sell.",
      "url": "https://finnhub.io/api/news?id=e4e4a458d4d5024fa4c4b1139ad3ff96dcd5046c6070aec049553cc8841d39a8"
    }
  }
]